On-Demand Event

Highlights from the Latest ODYSSEY OUTCOMES Data: The Role of PCSK9 Inhibition Post-ACS

Original air date:
Thursday, February 21, 2019

Running time: 1:01:03 minutes


Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FCCS
Lawrence A. Leiter, MD, FRCPC, FACP, FACE, FAHA, FACC
G.B. John Mancini, MD, FRCPC, FACP, FACC

Learning Objectives:

  • Review highlights of high CV risk (post ACS) patient profiles and the role and place of PCSK9i alirocumab in their treatment pathway
  • Discuss the latest ODYSSEY OUTCOMES data and subsequent sub-analysis
  • Describe the urgency to treat specific high CV risk patient profiles

Language: English

Therapeutic areas: Cardiology/Vascular Disease, Internal Medicine